Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation
Toshiyuki Miyata1, Rina Kimura, Yoshihiro Kokubo
1Research Institute, National Cardiovascular Center, Suita, Osaka, Japan. miyata@ri.ncvc.go.jp
Insights
Ethnic variations in disease mutations necessitate population-specific research. In Japanese individuals, protein S mutation K196E is a significant genetic risk factor for deep vein thrombosis, requiring targeted screening.
Area of Science:
- Genetics and Molecular Biology
- Thrombophilia and Hemostasis Research
- Population Health Studies
Background:
- Disease-associated mutations exhibit varying frequencies across ethnic groups, underscoring the need for ethnicity-specific investigations.
- Previous studies have indicated ethnic disparities in the genetic underpinnings of thrombophilia.
Purpose of the Study:
- To investigate the prevalence of deficiencies in plasma proteins C, S, antithrombin, and plasminogen within the Japanese population.
- To identify genetic factors contributing to deep vein thrombosis (DVT) in this demographic.
- To assess the clinical significance of the protein S K196E mutation in the Japanese population.
Main Methods:
- Conducted a large-scale analysis of plasma activities for proteins C, S, antithrombin, and plasminogen in the general Japanese population.
- Evaluated the genetic contribution of specific mutations, including protein S K196E, to the risk of deep vein thrombosis.
- Estimated allele frequencies and calculated the potential number of affected individuals.
Main Results:
- Prevalence of deficiencies: Protein C (0.13%), antithrombin (0.15%), protein S (1.12%), and plasminogen (4.29%).
- Identified protein S mutation K196E as a significant genetic risk factor for DVT in the Japanese population, with an estimated allele frequency of 0.009.
- Approximately 1 in 12,000 Japanese individuals may be homozygous for the K196E allele, potentially affecting up to 10,000 people.
Conclusions:
- A substantial portion of the Japanese population carries the protein S E allele, increasing their risk for deep vein thrombosis.
- The high frequency and strong association of the protein S K196E mutation with DVT suggest the value of large-scale screening.
- Individuals identified with this allele should be advised to mitigate environmental risk factors associated with DVT.
Abstract:
There is mounting evidence that mutations associated with a given disease arise with different frequencies among ethnic groups, thus ethnicity-specific studies are needed to identify causative mutations and properly assess risk. In particular, ethnic differences in the genetic background of thrombophilia have been reported. We recently conducted a large-scale analysis of the plasma activities of proteins C, S, antithrombin, and plasminogen within the Japanese general population. We found age- and sex-related differences and estimated the prevalence of deficiencies of protein C (0.13%), antithrombin (0.15%), protein S (1.12%), and plasminogen (4.29%). We also evaluated the genetic contribution to deep vein thrombosis and found that protein S mutation K196E is a genetic risk factor in the Japanese population. We estimated allele frequency to be 0.009, suggesting that 1 of 12,000 Japanese may be homozygous for the E allele, thus possibly as many as 10,000 individuals. Accordingly, a substantial proportion of the Japanese population carries the protein S E allele and is at risk of developing deep vein thrombosis. Given the frequency of this mutation and its strong correlation with deep vein thrombosis, it may be valuable to conduct a large-scale screening for this allele and advise concerned persons to avoid environmental risk factors known to be associated with deep vein thrombosis.
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Cancer Prevention
Some...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pleiotropy

